Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies

Félix Lugo Salcedo MD, Zuramis Estrada Blanco MD

Abstract

Vaginal laser therapy is a non-hormonal treatment option for vulvovaginal atrophy (VVA), a component of the genitourinary syndrome of menopause. Through a microablative and/ or thermal effect on atrophic vaginal epithelium, laser therapy activates growth factors that increase vascularity and collagen production. Laser and ospemifene are complementary treatments: the laser’s effects on intra- and extracellular water are supported by the activity of ospemifene at estrogen receptors to restore vaginal epithelium and natural lubrication. This article reports the clinical course of two women with dyspareunia preventing sexual intercourse who were treated with ospemifene and laser therapy. The woman in case 1 had extreme vaginal stenosis and severe VVA symptoms. CO2 laser therapy accompanied by estriol vaginal gel and vaginal moisturizer was unsuccessful. After ospemifene and three sessions of laser therapy, followed by vaginal ring resection and continued physiotherapy-directed mechanical dilation of the vagina, she was asymptomatic within 6 months. The woman in case 2 had severe VVA, which had prevented penetration for 2 years. Ospemifene was administered for 1 month to prepare the vaginal epithelium for photothermal therapy. A single erbium:YAG laser session and continued ospemifene treatment improved her symptoms sufficiently to allow her to resume sexual relations within 2 months.

Article Details

Article Type

Case Report

DOI

10.7573/dic.2020-3-7

Categories

Publication Dates

Accepted: ; Published: .

Citation

Lugo Salcedo F, Estrada Blanco Z. Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies. Drugs in Context 2020; 9: 2020-3-7. DOI: 10.7573/dic.2020-3-7

Article Views

Monthly article views (last 11 months)

Drugs in Context PubMed Central
Source HTML views PDF downloads Totals
Drugs in Context since September 15, 2025 28 0 28
PubMed Central since November 1, 2024 77 28 105
Totals 105 28 133
Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.